Brief: TYK Medicines Says Asandeutertinib Mesylate Tablets (TY-9591) Obtains Conditional Marketing Approval From NMPA
27/08/2026 17:04
BRIEF-TYK Medicines Says Asandeutertinib Mesylate Tablets (TY-9591) Obtains Conditional Marketing Approval From NMPA Aug 27 (Reuters) - TYK Medicines Inc 2410.HK:
ASANDEUTERTINIB MESYLATE TABLETS (TY-9591) OBTAINS CONDITIONAL MARKETING APPROVAL FROM NMPA
Further company coverage: 2410.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on TYK Medicines
See all newsBrief: TYK Medicines Says Chairman Buys 635,000 H Shares Between Sept 8 And Sept 10, 2026
Brief: Tyk Medicines Says Chairman Purchases Co's Shares On Open Market
Brief: TYK Medicines Says Asandeutertinib Mesylate Tablets (TY-9591) Obtains Conditional Marketing Approval From NMPA
Brief: TYK Medicines Files Legal Proceedings Against Sichuan Huiyu Pharmaceutical Over TY-9591 Agreements
Brief: Tyk Medicines Enters License And Collaboration Agreement With Qilu For Ty-9591 In China